Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company based in Grove City, Ohio.

Established in 2020, Forge focuses on enabling access to life-changing gene therapies, guiding them from concept to reality. The company operates a state-of-the-art 200,000-square-foot cGMP facility known as "The Hearth," which features 20 cGMP suites and 20,000L of bioreactor capacity, primarily dedicated to AAV (Adeno-Associated Virus) manufacturing. Forge offers comprehensive services for gene therapy programs, including AAV and plasmid DNA manufacturing, process and analytical development, and regulatory support. The company also has a two-candidate pipeline, with its lead candidate FBX-101 aimed at treating Crab A disease. With a commitment to a patients-first approach, Forge partners with scientists, physicians, biotech and pharma companies, and patient advocacy groups to accelerate the development of transformative medicines for rare genetic diseases.